This is a summary of the European public assessment report (EPAR) for Brimica Genuair. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Brimica Genuair. For practical information about using Brimica Genuair, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Brimica Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Therapeutic Area (MeSH)
N/AATC Code
R03AL05
ATC Item
formoterol and aclidinium bromide
Pharmacotherapeutic Group
Drugs for obstructive airway diseases
Active Substance (Summary)
N/AINN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| formoterol fumarate dihydrate | N/A | Aluminum sulfate |
| aclidinium bromide | N/A | 阿地溴铵 |
EMA Name
Brimica Genuair
Medicine Name
Brimica Genuair
Aliases
N/ANo risk management plan link.
